levonorgestrel has been researched along with fulvestrant in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Damián-Matsumura, P; García, GA; Grillasca, I; Lemus, AE; Pérez-Palacios, G; Reyes, M; Santillán, R | 1 |
| Arzate, H; Chimal-Monroy, J; Enríquez, J; García, GA; Herrero, B; Larrea, F; Lemus, AE; Pérez-Palacios, G | 1 |
| Abraham, T; Arian, SE; Bartels, CB; Cayton, KC; Chuong, FS; Holthouser, K; Segars, JH | 1 |
2 review(s) available for levonorgestrel and fulvestrant
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
An Evidence-based Approach to the Medical Management of Fibroids: A Systematic Review.
Topics: Androgens; Aromatase Inhibitors; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Curcumin; Delayed-Action Preparations; Drugs, Chinese Herbal; Estradiol; Estrenes; Estrogen Receptor Antagonists; Evidence-Based Medicine; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Intrauterine Devices, Medicated; Leiomyoma; Levonorgestrel; Medroxyprogesterone Acetate; Mifepristone; Neoadjuvant Therapy; Norpregnadienes; Oximes; Plant Extracts; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tea; Uterine Myomectomy; Uterine Neoplasms; Vitamin D; Vitamins | 2016 |
3 other study(ies) available for levonorgestrel and fulvestrant
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Assessment of the oestrogenic activity of the contraceptive progestin levonorgestrel and its non-phenolic metabolites.
Topics: Animals; beta-Galactosidase; Binding, Competitive; Contraceptive Agents, Female; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Humans; Levonorgestrel; Pituitary Gland, Anterior; Rats; Rats, Wistar; Receptors, Estrogen; Receptors, Progesterone; Recombinant Fusion Proteins; Saccharomyces cerevisiae | 2001 |
The effects of synthetic 19-norprogestins on osteoblastic cell function are mediated by their non-phenolic reduced metabolites.
Topics: 5-alpha Reductase Inhibitors; Animals; Calcification, Physiologic; Calcium; Cell Differentiation; Cell Proliferation; Cells, Cultured; Estradiol; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Finasteride; Fulvestrant; Humans; Levonorgestrel; Norethindrone; Osteoblasts; Osteocalcin; Phenols; Progesterone Congeners; Rats; Rats, Wistar | 2007 |